Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,534.00    70.00 (2.84%)
Bid:
2,532.00
Ask:
2,534.00
Spread: 2.00 (0.079%)
Market Cap: £8.14b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

Today 07:00

RNS Number : 2843J
Bunzl PLC
23 June 2026
 

23 June 2026

 BUNZL PRE-CLOSE STATEMENT

2026 outlook upgraded; bolt-on acquisition completed in Australia

Bunzl plc, the specialist international distribution and services Group, is updating the market today prior to entering its closed period for the six months ending 30 June 2026.

Group revenue over the first half of 2026 is expected to grow by around 4% at constant exchange rates, with underlying revenue growth of around 3%. We expect growth to be supported by inflation across certain categories in the second quarter, with product-cost increases driven by geopolitical events, and we are also seeing encouraging volume growth. Volume growth is expected to be driven by North America, with good growth in our Distribution business. Our Distribution business continues to see operational progress as a result of actions taken, with encouraging volume growth across customers and supported by the additional benefit from new business wins that were achieved towards the end of last year. Over the first half, acquisitions, net of disposals, are expected to contribute growth of around 1% to the Group, and currency is expected to have a relatively neutral impact on revenue at actual exchange rates.

The Group expects good year-on-year growth in adjusted operating profit over the first half at constant exchange rates. Operating margin is expected to be up modestly year-on-year due to the net impact of inflation in the second quarter, much of which is expected to be temporary in nature, and the annualisation of Nisbets synergies.

While we remain mindful of continuing macroeconomic and geopolitical uncertainties, we are encouraged by our performance and upgrade our 2026 guidance. The Group now expects revenue growth at constant exchange rates to be driven by modest underlying revenue growth, supported by some inflation, alongside a small benefit from acquisitions. Our operating margin guidance is unchanged and we continue to expect it to be slightly down year-on-year.

In April, Bunzl completed the acquisition of Scientifix Group, an Australian distributor of critical products and services to the Life Sciences and Biotechnology sectors that will expand the category offering of our existing business. In the 12 months to June 2026, the business is expected to generate revenue of AUD 18 million (c.£9 million).

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

"Bunzl is expecting to deliver an improved performance in the first half, with continued underlying growth and robust profitability, demonstrating the resilience and agility of our business model. Furthermore, I am pleased that our North America Distribution business has achieved the good operational progress we had expected, with the business' responsiveness, agility and high service levels largely restored. We continue to expect 2026 to be a foundation for future profit growth.

I am also delighted to welcome Scientifix into the Group, a company that is an excellent strategic fit with our existing healthcare business in Australia, and further enhances our exposure to this attractive value-added sector. Our acquisition pipeline remains active and we continue to expect 2026 to be an improved year for acquisitions. We continue to see significant opportunities to further consolidate our fragmented global markets, and remain confident in our ability to generate long-term compounding growth and value creation for all of our stakeholders."

Conference call

There will be a live analyst and investor conference call and Q&A session from 8.00am (BST) today, hosted by Richard Howes (Chief Financial Officer). A replay will be available later in the day.

Dial-in number: + 44 20 3936 2999 / Access code: 534897

Enquiries:

Bunzl plc (Tel: +44 (0)20 7725 5000)

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Sunita Entwisle, Head of Investor Relations and Communications

Teneo (Tel: +44 (0)20 7353 4200)

Martin Robinson

Kate Somerville

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBRGDLXGDDGLD
Date   Source Headline
24th Apr 20247:00 amRNSTrading Statement
22nd Apr 20244:36 pmRNSDirector/PDMR Shareholding
18th Apr 20248:00 amRNSAdditional Listing
11th Apr 20248:00 amRNSAdditional Listing
3rd Apr 20245:28 pmRNSDirector/PDMR Shareholding
3rd Apr 20249:09 amRNSDirector/PDMR Shareholding
2nd Apr 20241:50 pmRNSTotal Voting Rights
21st Mar 20248:00 amRNSAdditional Listing
15th Mar 20243:28 pmRNSAnnual Financial Report
7th Mar 20248:00 amRNSAdditional Listing
5th Mar 20245:05 pmRNSDirector/PDMR Shareholding
4th Mar 20243:03 pmRNSDirector/PDMR Shareholding
1st Mar 202411:35 amRNSTotal Voting Rights
28th Feb 20243:17 pmRNSDirector/PDMR Shareholding
27th Feb 20245:26 pmRNSDirector/PDMR Shareholding
26th Feb 202410:30 amRNSDividend Declaration
26th Feb 20247:00 amRNSFinal Results
26th Feb 20247:00 amRNSAcquisition
5th Feb 20242:20 pmRNSDirector/PDMR Shareholding
1st Feb 20245:08 pmRNSTotal Voting Rights
12th Jan 20244:54 pmRNSDirector/PDMR Shareholding
11th Jan 20243:50 pmRNSDirector/PDMR Shareholding
2nd Jan 202410:57 amRNSTotal Voting Rights
15th Dec 20235:10 pmRNSHolding(s) in Company
14th Dec 20237:00 amRNSTrading Statement
8th Dec 20235:32 pmRNSDirector/PDMR Shareholding
1st Dec 202311:32 amRNSTotal Voting Rights
20th Nov 20236:30 pmRNSPublication of Admission Particulars
3rd Nov 20239:30 amRNSDirector Declaration
2nd Nov 20232:29 pmRNSDirector/PDMR Shareholding
1st Nov 202311:24 amRNSTotal Voting Rights
1st Nov 20239:00 amRNSBlock listing Interim Review
24th Oct 20237:00 amRNSTrading Statement
6th Oct 20235:08 pmRNSDirector/PDMR Shareholding
4th Oct 20231:40 pmRNSDirector/PDMR Shareholding
2nd Oct 20231:34 pmRNSTotal Voting Rights
2nd Oct 20231:33 pmRNSDirector/PDMR Shareholding
26th Sep 20232:10 pmRNSDirector/PDMR Shareholding
1st Sep 20232:30 pmRNSTotal Voting Rights
31st Aug 202310:30 amRNSDirector/PDMR Shareholding
29th Aug 202310:00 amRNSDividend Declaration
29th Aug 20237:00 amRNSHalf-year Report
29th Aug 20237:00 amRNSAcquisition
15th Aug 20237:00 amRNSAcquisition
2nd Aug 20233:45 pmRNSDirector/PDMR Shareholding
1st Aug 202311:17 amRNSTotal Voting Rights
13th Jul 20234:20 pmRNSDirector/PDMR Shareholding
13th Jul 20237:00 amRNSOutcome of audit tender process
11th Jul 20234:50 pmRNSDirector/PDMR Shareholding
6th Jul 202310:44 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.